All In Biotech

Drug Trial Radar · NCT00338650

Treatment of the Human Anti-TNF Monoclonal Antibody Adalimumab in Moderate to Severe Crohn's Disease With Previous Exposure to Infliximab (CHOICE)

A Multi-Center, Open-Label Treatment Protocol of the Human Anti-TNF Monoclonal Antibody Adalimumab in Patients With Moderate to Severe Crohn's Disease With Previous Exposure to Infliximab

Last checked: Nov 20, 2026Latest source record: Nov 29, 2007 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

1,000

Actual

Start

Jun 2006

Primary completion

Not stated

Study completion May 2007

Sponsor

Lead sponsor
AbbottIndustry
Sponsor type
Industry
First posted
Jun 20, 2006

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Non randomized
Model
Single group
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The primary objective of this study is to make adalimumab available to patients suffering from moderately to severely active Crohn's Disease who have failed to respond to, lost response to, or are intolerant to infliximab, and to evaluate safety

Conditions

  • Crohn's Disease

Interventions

  • adalimumabDrug

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. AEs, laboratory data, physical examinations and vital signs

Locations

97 sites in 1 country. Site status is shown where the registry gives one.

  • Site not named

    Birmingham, Alabama

  • Site not named

    Jonesboro, Arkansas

  • Site not named

    Little Rock, Arkansas

  • Site not named

    Roseville, California

  • Site not named

    San Francisco, California

  • Site not named

    Englewood, Colorado

  • Site not named

    Wheat Ridge, Colorado

  • Site not named

    Bridgeport, Connecticut

  • Site not named

    Hamden, Connecticut

  • Site not named

    Clearwater, Florida

  • Site not named

    Gainesville, Florida

  • Site not named

    Gainesville, Florida

  • Site not named

    Hollywood, Florida

  • Site not named

    Jacksonville, Florida

  • Site not named

    Jacksonville, Florida

  • Site not named

    Miami, Florida

  • Site not named

    North Miami Beach, Florida

  • Site not named

    Winter Park, Florida

  • Site not named

    Atlanta, Georgia

  • Site not named

    Atlanta, Georgia

  • Site not named

    Atlanta, Georgia

  • Site not named

    Conyers, Georgia

  • Site not named

    Marietta, Georgia

  • Site not named

    Savannah, Georgia

  • Site not named

    Arlington Heights, Illinois

  • Site not named

    Moline, Illinois

  • Site not named

    Rockford, Illinois

  • Site not named

    Columbus, Indiana

  • Site not named

    Indianapolis, Indiana

  • Site not named

    Indianapolis, Indiana

  • Site not named

    Clive, Iowa

  • Site not named

    Davenport, Iowa

  • Site not named

    Overland Park, Kansas

  • Site not named

    Topeka, Kansas

  • Site not named

    Lexington, Kentucky

  • Site not named

    Annapolis, Maryland

  • Site not named

    Chevy Chase, Maryland

  • Site not named

    Lutherville, Maryland

  • Site not named

    Silver Spring, Maryland

  • Site not named

    Boston, Massachusetts

Showing 40 of 97 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.